Evidence map›Paper›PMID 42041243›Full record

ArticleTurkish journal of haematology : official journal of Turkish Society of Haematology2026

Clinical Phenotypes and Glycopeptide Escalation Patterns in Pediatric Febrile Neutropenia: Associations with Short-Term Outcomes and Acute Kidney Injury Risk

Neryal Tahta, Zuhal Önder Siviş, Mehtap Ertekin, Burçak Tatlı Güneş, Şilem Özdem Alataş, Esin Özcan, Salih Gözmen

Abstract read
In one paragraph

Article in Turkish journal of haematology : official journal of Turkish Society of Haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Interpreting Glycopeptide Escalation and Acute Kidney Injury with CautionTurkish journal of haematology : official journal of Turkish Society of Haematology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Neryal TahtaUniversity of Health Sciences Türkiye, İzmir City Hospital, Clinic of Pediatric Hematology Oncology, İzmir, TürkiyeORCID 0000-0001-6939-1570
Zuhal Önder SivişUniversity of Health Sciences Türkiye, İzmir City Hospital, Clinic of Pediatric Hematology Oncology, İzmir, TürkiyeORCID 0000-0002-3499-1864
Mehtap ErtekinUniversity of Health Sciences Türkiye, İzmir City Hospital, Clinic of Pediatric Hematology Oncology, İzmir, TürkiyeORCID 0000-0003-1622-890X
Burçak Tatlı GüneşUniversity of Health Sciences Türkiye, İzmir City Hospital, Clinic of Pediatric Hematology Oncology, İzmir, TürkiyeORCID 0000-0001-7080-2373
Şilem Özdem AlataşUniversity of Health Sciences Türkiye, İzmir City Hospital, Clinic of Pediatric Infectious Diseases, İzmir, TürkiyeORCID 0000-0002-2662-5039
Esin ÖzcanUniversity of Health Sciences Türkiye, İzmir City Hospital, Clinic of Pediatric Hematology Oncology, İzmir, TürkiyeORCID 0000-0002-0867-1752
Salih GözmenUniversity of Health Sciences Türkiye, İzmir City Hospital, Clinic of Pediatric Hematology Oncology, İzmir, TürkiyeORCID 0000-0002-8585-9628

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Febrile neutropenia (FN) in pediatric oncology is a clinically heterogeneous syndrome in which early antibiotic escalation decisions are frequently driven by non-specific severity cues. We aimed to identify baseline clinical phenotypes of pediatric FN, to describe early glycopeptide escalation patterns across these phenotypes, and to examine their associations with short-term outcomes and acute kidney injury (AKI). Materials and Methods: We conducted a retrospective cohort study including 106 FN episodes experienced by 82 pediatric oncology patients initially treated with piperacillin-tazobactam monotherapy. Baseline clinical and laboratory variables available within the first 6 hours of FN onset were used for unsupervised k-means clustering to derive latent clinical phenotypes. Early glycopeptide escalation was defined as the initiation of vancomycin or teicoplanin within 48 hours. Associations with clinical outcomes on day 7 and AKI were evaluated using multivariable cluster-robust regression and inverse probability of treatment weighting. Results: Three distinct FN phenotypes were identified: a high-inflammatory/mucositis-dominant phenotype (39.6%), a hemodynamically severe phenotype (22.6%), and a lower-severity phenotype (37.7%). Early glycopeptide escalation occurred in 26.4% of episodes and was disproportionately concentrated in the high-inflammatory and hemodynamically severe phenotypes. AKI developed in 10.4% of FN episodes and clustered predominantly within escalation-prone phenotypes. After adjustment, early escalation was not associated with improved day-7 clinical success but was associated with a higher observed risk of AKI. Conclusion: Pediatric FN comprises distinct clinical phenotypes that differentially drive antibiotic escalation behavior and renal injury risk. A phenotype-informed approach may help to optimize escalation decisions and potentially reduce preventable toxicity. However, given the observational design of this study, these associations should be interpreted with caution.

Indexed as

Acute Kidney InjuryAnti-Bacterial AgentsFebrile NeutropeniaGlycopeptidesAdolescentChildChild, PreschoolFemaleHumansInfantMalePhenotypeRetrospective StudiesRisk FactorsTreatment OutcomeVancomycinAnti-Bacterial AgentsGlycopeptidesVancomycinAcute kidney injuryAntimicrobial stewardshipClinical phenotypesFebrile neutropeniaGlycopeptide antibioticsNephrotoxicityPediatric oncology

Identifiers

PMID42041243
PMCPMC13225694

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.